Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]TNP-2198 in Healthy Males
NCT06137573Phase 1Completed
- Sponsor
- TenNor Therapeutics
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifasutenizol in Helicobacter pylori infection, sponsored by TenNor Therapeutics. Primary endpoints: Cumulative excretion rate of total radioactivity in excreta (urine and feces), Pharmacokinetics (PK) (AUC0-inf) for TNP-2198 and total radioactivity and 2 more. Started Jul 2022; status: completed.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06137573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137573.